-
Adams RD, Fisher CM, Hakim S, Ojeman R, Sweet W. Symptomatic occult hydrocephalus
with normal cerebrospinal pressure: a treatable syndrome. N Engl J Med 1965; 273:
117-126.
- American Psychiatric Association. Diagnostic and statistical manual
of mental disorders. 4th edition (DSM IV). Washington DC: American Psychiatric
Association; 1994.
- Bodich NC, Offen WW, Levey A, Cutler NR, Gautier SG,
Satlin A et al. Effects of xanomeline, a selective muscarinic receptor agonist,
on cognitive function and behavioural symptoms in Alzheimer's disease. Arch Neurol
1997; 54: 465-473.
- BOE 26-10-1983. Ley de Reforma del Código Civil
en materia de tutela.
- BOE 29-04-1986. Ministerio de Sanidad. Ley General
de Sanidad.
- BOE 24-11-1995. Código Penal.
- BOE 28-10-1999. Ley
de Reforma del Código Civil en Materia de Tutela.
- BOE Real Decreto
772/1997. Dirección General de Tráfico. Reglamento General de Conductores.
-
BOE 05-03-1993. Real Decreto por el que se aprueba el Reglamento de Annas.
-
Bonet J. Código Civil concordado y con jurisprudencia. Madrid: Civitas;
1993.
- Caplan LR. Binswanger's disease-revisited. Neurology 1995; 45: 626-
638.
- Chacko R, Hurley RA, Jankovic J. Cozapine use in diffuse Lewy body
disease. J Neuropsychiatry Clin Neurosci 1993; 5: 206-208.
- Corey-Bloom J,
Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA
713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients
with mild to moderately severe Alzheimer's disease. Int J Geriatric Psychopharmacol
1998; 1: 55-65.
- Cycloserine enhances implicit memory in Alzheimer patients.
Neurology 1996; 46: 420-424.
- Cycloserine enhances implicit memory in Alzheimer
patients.Neurology 1996; 46: 420-424.
- Friedhoff LT, Rogers SL. Donepezillengthens
time to loss of activities of daily living in patients with mild to moderate Alzheimer'
disease: results of a preliminary evaluation. Neurology 1997; 48 (suppl): A100.
- Fulton B, Benfield P. Galantamine. Drugs Again 1996; 9: 60-65.
- Gregory
CA, Hodges JR. Frontotemporal dementia: use of consensus criteria and prevalence
of psychiatric features. Neuropsychiatry, Neuropsychology and Behavioural Neurology
1996; 9: 145-153.
- Gustafson L. Clinical classification of dementia conditions.
Act Neurol Scand 1992; 139 (suppl): 16-20.
- Hughes CP, Siegal BA, Coxe WS,
Gado MH, Grubb RL, Coleman RE, Berg L. Adult idiopathic communicating hydrocephalus
with and without shunting. J Neurol Neurosurg Psychiatry 1978; 41: 961-971.
-
Jones GM Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous
nicotine on attention, information processing and short-term memory. Psychopharmachology
1992; 108: 485-494.
- Katzman R. Normal pressure hydrocephalus. En: Wells
CE (ed). Dementia. 2nd ed. Philadelphia: FA Davis; 1977. p. 69-92.
- Knapp
MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized
controlled trial of high-dose tacrine in patients with Alzheimer's disease. The
Tacrine Study Group. JAMA 1994; 271: 985-991.
- Kumar R. Efficacy and safety
of SB 202026 as a symptomatic treatment for Alzheimer's disease. Ann Neuro11996;
40: 504.
- Mc Keith IG, Galasco D, Kosaka K, Perry EK, Dicskon DW, Hansen
LA et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia
with Lewy bodies (DLB): Report of the consortium on DLB international workshop.
Neurology 1996; 47: 1113-24.
- Neary D. Dementia of frontal lobe type. J Am
Geriatr Soc 1990; 38: 71- 72.
- Piedrabuena E. Aspectos legales de las demencias.
En: Alberca R, Lopez-Pousa S (Eds). Enfermedad de Alzheimer y otras demencias.
Madrid: IM&C; 1998. p. 117-124.
- Portal Alzheimer 2000. ¿Qué
es una demencia? Alzheimer-online ltd Publishing: consejos [publicación
periódi-
ca online] 2002. Disponible en URL: http://www.alzheimer-online.org
-
Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global
function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study.
Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031.
- Rogers SL,
Farlow MR, Doody RS, Mohs R, Friedhoff LT and Donepezil study group. A 24-weed,
double-blind, placebo-controlled trial of donepezil in patients with A1zheimer'
disease. Neurology 1998; 50: 136-144.
- Rogers SL, Friedhoff LT. The efficacy
and safety of donepezil in patients with A1zheimer's disease: Results of a US
multicenter, randomised, double-blind, placebo-controlled trial. Dementia 1996;
7: 293-303.
- Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco
P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease:
international randomised controlled trial. Br Med J 1999; 318: 633-640.
-
Sano M, Ernesto C, Thomas RG, Klauber MR, Schaufer K, Grundman M et al. A controlled
trial of seleginine, alfa-tocopherol, or both as treatment for Alzheimer's disease.
N engl J Med 1997; 336: 1216-1222.
- SHEP Cooperative Research Group. Prevention
of stroke by antihipertensive drug treatment in older persons with isolated Systolic
Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3,255- 3264.
-
Sociedad Española de Psiquiatría. Consenso Español sobre
Demencias. Madrid: DRUG FARMA; 2000. p. 93-129.
- Summer WK, Majovski LV, Marsh
GM, Tachiki K Kling A. Oral tetrahydroaminoacridine in long-term treatment of
senile dementia, Alzheimer type. New Eng J Med 1986; 315: 1241-1245.
- Waters
CH, Miller CA. Autosomal dominant Lewy body parkinsonism in a four-generation
family. Ann Neurol 1994; 35: 59-64.
- Wiseman LR, Mc Tavish D. Seleginine.
A review of its clinical efficacy in Parkinson's disease and its clinical potential
in Alzheimer's disease. CNS Drugs 1995; 4: 230-246.
- World Health Organization.
The ICD-10 Classification of mental and behavioural disorders. Geneva: World Health
Organization; 1992. |
